

Medibio Signs Fourth Pilot Agreement with Compass Group for ilumen™

Highlights:

- Up to 150 Compass employees in its Defence Division in the United Kingdom will take part in a 4-week ilumen™ well-being pilot commencing in November.
 - ilumen™ will provide participants with access to a mobile and web application for early screening of mental health symptoms.
 - Compass Contract Services (UK) Limited, part of Compass Group PLC (Compass Group), is the world's leading food service provider which employs or engages 600,000 people and generates annual revenues of £23.2 Billion.
 - This is the fourth commercial agreement with Compass for the use of Medibio's corporate health product. The company is very pleased with the commercial momentum for ilumen™.
-

Melbourne, Australia and Minneapolis, MN – 30 August 2019: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a health technology company announces that it has signed a fourth commercial agreement with Compass Group for its corporate health product, ilumen™.

Compass Group is a British multinational and the world's leading food service company with annual revenues of £23.2 billion. It operates in around 45 countries and employs and engages c.600,000 people worldwide. Compass provides support services across the core sectors of Defence, Offshore & Remote; Business & Industry; Healthcare & Seniors; Education and Sports & Leisure.

As part of the Health & Well-being element of its global 'Purpose' strategy, Compass Group implements various programs to support and improve the mental well-being and physical health of its workforce and its clients' workforce. ilumen™ fits into this strategy by providing

ASX Announcement

Medibio Limited – 30 August 2019



participants with early screening for symptoms of depression, anxiety, and stress. The ilumen™ biometric data and subjective assessments provide users with a ‘well-being snapshot’ that they use to monitor and make improvements over time; whilst also providing Compass management with de-identified aggregate data to better support and manage the mental well-being of their workforce.

“The signing of this fourth pilot agreement demonstrates the importance of this initiative to Compass Group,” said Jennifer Solitario, Sr. VP, Corporate Health. “We are pleased to partner with Compass in this continuing relationship and support them in their effort to improve the mental well-being of their workforce. We are also very pleased with the commercial momentum we now have for ilumen™.”

– ENDS –

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcm Markets.com and www.asx.com.au.

Further Information:	Website: www.medibio.com.au
Medibio Media Enquiries: Kristi Hamilton Director, Strategic Communications Medibio Limited kristi.hamilton@medibio.com.au T: +1 952 232 0934	Australian Investor Enquiries: Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0) 412 036 231
Corporate Health Enquiries: Renee Stanton-Horne Operations and Account Manager renee.stanton.horne@medibio.com.au	